Only a fraction of patients with hemophilia A develop a neutralizing antibody (inhibitor)
response to therapeutic infusions of factor VIII. Our present understanding of the underlying …

Hemophilia A is a bleeding disorder characterized by the absence or dysfunction of blood
coagulation factor VIII (FVIII). Patients are treated with regular infusions of FVIII concentrate …

Interaction of factor VIII (FVIII) with von Willebrand factor (VWF) is mediated by the VWF D′
D3 domains and thrombin-mediated release is essential for hemostasis after vascular injury …

Background: Low‐density lipoprotein (LDL) receptor family members contribute to the
cellular uptake of factor VIII. How von Willebrand factor fits into this endocytic pathway has …

Background Hemophilia A arises from dysfunctional or deficient coagulation factor (F) VIII
and leads to inefficient fibrin clot formation and uncontrolled bleeding events. The …

The development of inhibitory antibodies to therapeutic factor VIII is the major complication
of replacement therapy in patients with hemophilia A. The first step in the initiation of the anti …

A main complication of treatment of patients with hemophilia A is the development of anti–
factor VIII (fVIII) antibodies. The immunogenicity of fVIII potentially is a function of its …

Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a central inhibitor of matrix-degrading
and sheddase families of metalloproteinases. Extracellular levels of the inhibitor are …

Lysine residues are implicated in driving the ligand binding to the LDL receptor family.
However, it has remained unclear how specificity is regulated. Using coagulation factor VIII …

Abstract Development of neutralizing Abs to blood coagulation factor VIII (FVIII) provides a
major complication in hemophilia care. In this study we explored whether modulation of the …